Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis

被引:102
作者
Terrier, Benjamin [1 ,2 ]
Carrat, Fabrice [3 ]
Geri, Guillaume [1 ,2 ]
Pol, Stanislas [4 ]
Piroth, Lionel [5 ]
Halfon, Philippe [6 ]
Poynard, Thierry [7 ]
Souberbielle, Jean-Claude [8 ]
Cacoub, Patrice [1 ,2 ]
机构
[1] Univ Paris 06, Dept Internal Med, Paris, France
[2] Univ Paris 06, CNRS, UMR 7211, Paris, France
[3] Univ Paris 06, Hop St Antoine, AP HP, UMR S707,INSERM, Paris, France
[4] Hop Cochin, Dept Hepatol, Paris, France
[5] Univ Bourgogne, CHU, Dept Infect Dis, Dijon, France
[6] Lab Alphabio, Dept Virol, Marseille, France
[7] Grp Hosp Pitie Salpetriere, Dept Hepatol, F-75013 Paris, France
[8] Univ Paris 05, Hop Necker Enfants Malad, Dept Physiol, Paris, France
关键词
Hepatitis C virus; Human immunodeficiency virus; Chronic hepatitis; 25-OH vitamin D; Severe fibrosis; IMMUNODEFICIENCY-VIRUS INFECTION; RENAL INTERSTITIAL FIBROSIS; ANTIRETROVIRAL THERAPY; LIVER-DISEASE; D DEFICIENCY; 25-HYDROXYVITAMIN D; MORTALITY; ASSOCIATION; CELLS; PREVALENCE;
D O I
10.1016/j.jhep.2011.01.041
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Recent findings in hepatitis C virus (HCV)-monoinfected patients have shown a correlation between low serum levels of 25-OH vitamin D3 [25(OH)D3] and severe liver fibrosis and low sustained virologic response to therapy. Data are lacking in HIV-HCV coinfected patients. Methods: One hundred and eighty nine HIV-HCV coinfected patients, who received >= 80% of interferon (IFN) plus ribavirin therapy, were analyzed for baseline serum 25(OH)D3 levels. Correlations between serum 25(OH)D3 levels, chronic hepatitis C features, HCV virologic response to antiviral therapy, and HIV infection characteristics were analyzed. Results: Mean serum 25(OH)D3 level was 18.5 +/- 9.8 ng/ml, including 162 (85%) patients with level <= 30 ng/ml. Serum 25(OH)D3 levels were significantly correlated with the histological Metavir fibrosis score (r = -0.16; p = 0.027). Patients with severe fibrosis (Metavir F3/F4) had lower serum 25(OH)D3 levels compared to F2 and F1 patients (16.2 +/- 10.0 vs. 18.9 +/- 8.5 and 20.9 +/- 11.1 ng/ml, respectively; p = 0.06). In multivariate analysis, low serum 25(OH)D levels were independently associated with severe liver fibrosis (p = 0.04) and cold season (p = 0.0002). Serum levels of 25(OH)D3 were also significantly correlated with liver fibrosis as assessed by FibroTest (R) (r = -0.22; p = 0.008) and serum alpha 2-macroglobulin levels (r = -0.23; p = 0.006). In contrast, no correlation was found between 25(OH)D3 levels and HCV sustained virologic response to IFN-based therapy [OR 0.98 (0.95-1.01); p = 0.22]. No association was found between 25(OH)D3 levels and markers of HIV-related immunodeficiency. Conclusions: In HIV-HCV coinfected patients, low serum 25(OH)D3 levels correlate with severe liver fibrosis. In contrast, serum 25(OH)D3 levels are not linked to HCV virologic response to therapy or severity of immunodeficiency. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:756 / 761
页数:6
相关论文
共 32 条
[1]  
ABUMOUCH SM, 2009, HEPATOLOGY
[2]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[3]   Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells [J].
Artaza, Jorge N. ;
Norris, Keith C. .
JOURNAL OF ENDOCRINOLOGY, 2009, 200 (02) :207-221
[4]   Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: A descriptive cross-sectional study [J].
Bang, Ulrich Christian ;
Shakar, Shakil A. ;
Hitz, Mette Friberg ;
Jespersen, Mette Syberg ;
Andersen, Ove ;
Nielsen, Susanne Dam ;
Jensen, Jens-Erik Beck .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 42 (04) :306-310
[5]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[6]  
Brown TT, 2010, ANTIVIR THER, V15, P425, DOI [10.3851/IMP15021, 10.3851/IMP1502]
[7]   Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997 [J].
Cacoub, P ;
Geffray, L ;
Rosenthal, E ;
Perronne, C ;
Veyssier, P ;
Raguin, G .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1207-1214
[8]   Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].
Carrat, F ;
Bani-Sadr, F ;
Pol, S ;
Rosenthal, E ;
Lunel-Fabiani, F ;
Benzekri, A ;
Morand, P ;
Goujard, C ;
Pialoux, G ;
Piroth, L ;
Salmon-Céron, D ;
Degott, C ;
Cacoub, P ;
Perronne, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848
[9]   Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C [J].
Darby, SC ;
Ewart, DW ;
Giangrande, PLF ;
Spooner, RJD ;
Rizza, CR ;
Dusheiko, GM ;
Lee, CA ;
Ludlam, CA ;
Preston, FE .
LANCET, 1997, 350 (9089) :1425-1431
[10]   SUBNORMAL SERUM CONCENTRATION OF 1,25-VITAMIN-D IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - CORRELATION WITH DEGREE OF IMMUNE-DEFICIENCY AND SURVIVAL [J].
HAUG, C ;
MULLER, F ;
AUKRUST, P ;
FROLAND, SS .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04) :889-893